



(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 35/00 (2006.01)

A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2020/055480

(22) International Filing Date:

14 October 2020 (14.10.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/915,120 15 October 2019 (15.10.2019) US

(71) Applicant: DRAGONFLY THERAPEUTICS, INC.
[US/US]; 35 Gatehouse Drive, Waltham, MA 02451 (US).

(72) Inventors: BARUAH, Hemanta; 2513 Navarro Trail, Euless, TX 76039 (US). CHANG, Gregory, P.; 143 Saunders Street, Medford, MA 02155 (US). CHEUNG, Ann, F.; 25 Morningside Lane, Lincoln, MA 01773 (US). GRINBERG, Asya; 37 Follen Road, Lexington, MA 02421 (US). JHUO, Zong, Sean; 1105 Massachusetts Ave, Apt. 9E, Cambridge, MA 02138 (US). MCQUADE, Thomas, J.; 471 Commonwealth Ave, Apt. 4F, Boston, MA 02215 (US).

(74) Agent: MARTINEK, Sebastian et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTIBODIES TARGETING FLT3 AND USE THEREOF

FIG. 4A

RMA-hFLT3



(57) Abstract: Disclosed are proteins with antibody heavy chain and light chain variable domains that can be paired to form an antigen-binding site targeting FLT3 on a cell, pharmaceutical compositions comprising such proteins, and therapeutic methods using such proteins and pharmaceutical compositions, including for the treatment of cancer.